Top

Published in:

01-12-2019 | Mood Disorders | Original article

Bright light therapy with a head-mounted device for anxiety, depression, sleepiness and fatigue in patients with Parkinson’s disease

Authors: Jean-Marc Raymackers, Mariana Andrade, Eugenie Baey, Margaux Vanneste, Frédéric Evrard

Published in: Acta Neurologica Belgica | Issue 4/2019

Abstract

The beneficial effects of bright light therapy (BLT) on the disabling non-motor symptoms of Parkinson’s disease (PD) remain uncertain. The objective of this study was to investigate if daily BLT, with a head-mounted device (Luminette^®), has a beneficial effect on depression, anxiety, daytime sleepiness and fatigue in patients with PD. In this double-blind, placebo-controlled study, 16 patients with PD were randomized to receive either 1 month of BLT or 1 month of placebo therapy, separated by a 2-week washout period, in a crossover fashion. Patients completed questionnaires for the Hospital Anxiety and Depression Scale (HADS), the Epworth Sleepiness Scale (ESS) and the Fatigue Impact Scale (FIS) before and after each treatment period. The primary outcome measures were changed from baseline in scores between treatment groups. No significant changes were observed in the HADS anxiety scores and FIS scores after BLT and after placebo. The ESS scores decreased non-significantly only after BLT. A post hoc analysis of patients who had baseline ESS scores > 11 revealed a significantly greater decrease in ESS scores after BLT than after placebo. Future studies investigating the effect of BLT on sleepiness could focus specifically on patients with high ESS scores.

GBD 2016 Neurology Collaborators (2019) Global, regional, and national burden of neurological disorders, 1990–2016: a systematic analysis for the global burden of disease study 2016. Lancet Neurol 18:459–480. https://doi.org/10.1016/S1474-4422(18)30499-X CrossRef

MDS clinical diagnostic criteria for Parkinson’s disease—Postuma—2015—Movement Disorders—Wiley Online Library. https://onlinelibrary.wiley.com/doi/10.1002/mds.26424. Accessed 4 May 2019

Gallagher DA, Lees AJ, Schrag A (2010) What are the most important nonmotor symptoms in patients with Parkinson’s disease and are we missing them? Mov Disord 25:2493–2500. https://doi.org/10.1002/mds.23394 CrossRefPubMed

Chaudhuri KR, Healy DG, Schapira AHV, National institude for Clinical Excellence (2006) Non-motor symptoms of Parkinson’s disease: diagnosis and management. Lancet Neurol 5:235–245. https://doi.org/10.1016/S1474-4422(06)70373-8 CrossRefPubMed

Reijnders JSAM, Ehrt U, Weber WEJ et al (2008) A systematic review of prevalence studies of depression in Parkinson’s disease. Mov Disord 23:183–189. https://doi.org/10.1002/mds.21803 CrossRefPubMed

Richard IH (2005) Anxiety disorders in Parkinson’s disease. Adv Neurol 96:42–55PubMed

Aarsland D, Kramberger MG (2015) Neuropsychiatric symptoms in Parkinson’s disease. J Parkinsons Dis 5:659–667. https://doi.org/10.3233/JPD-150604 CrossRefPubMed

Tholfsen LK, Larsen JP, Schulz J et al (2015) Development of excessive daytime sleepiness in early Parkinson disease. Neurology 85:162–168. https://doi.org/10.1212/WNL.0000000000001737 CrossRefPubMed

Gjerstad MD, Alves G, Wentzel-Larsen T et al (2006) Excessive daytime sleepiness in Parkinson disease: is it the drugs or the disease? Neurology 67:853–858. https://doi.org/10.1212/01.wnl.0000233980.25978.9d CrossRefPubMed

10.

Bjørnarå KA, Dietrichs E, Toft M (2014) Clinical features associated with sleep disturbances in Parkinson’s disease. Clin Neurol Neurosurg 124:37–43. https://doi.org/10.1016/j.clineuro.2014.06.027 CrossRefPubMed

11.

Xiang Y, Xu Q, Sun Q et al (2019) Clinical features and correlates of excessive daytime sleepiness in Parkinson’s disease. Front Neurol. https://doi.org/10.3389/fneur.2019.00121 CrossRefPubMedPubMedCentral

12.

Cochen De Cock V, Bayard S, Jaussent I et al (2014) Daytime sleepiness in Parkinson’s disease: a reappraisal. PLoS One 9:e107278. https://doi.org/10.1371/journal.pone.0107278 CrossRefPubMedPubMedCentral

13.

Videnovic A, Golombek D (2013) Circadian and sleep disorders in Parkinson’s disease. Exp Neurol 243:45–56. https://doi.org/10.1016/j.expneurol.2012.08.018 CrossRefPubMed

14.

Videnovic A, Noble C, Reid KJ et al (2014) Circadian melatonin rhythm and excessive daytime sleepiness in Parkinson disease. JAMA Neurol 71:463–469. https://doi.org/10.1001/jamaneurol.2013.6239 CrossRefPubMedPubMedCentral

15.

Shirani A, St Louis EK (2009) Illuminating rationale and uses for light therapy. J Clin Sleep Med 5:155–163PubMedPubMedCentral

16.

PURLs: light therapy for nonseasonal major depressive disorder? PubMed—NCBI. https://www.ncbi.nlm.nih.gov/pubmed/27565102. Accessed 30 Apr 2019

17.

Perera S, Eisen R, Bhatt M et al (2016) Light therapy for non-seasonal depression: systematic review and meta-analysis. BJPsych Open 2:116–126. https://doi.org/10.1192/bjpo.bp.115.001610 CrossRefPubMedPubMedCentral

18.

Slama H, Deliens G, Schmitz R et al (2015) Afternoon nap and bright light exposure improve cognitive flexibility post lunch. PLoS One. https://doi.org/10.1371/journal.pone.0125359 CrossRefPubMedPubMedCentral

19.

Botanov Y, Ilardi SS (2013) The acute side effects of bright light therapy: a placebo-controlled investigation. PLoS One 8:e75893. https://doi.org/10.1371/journal.pone.0075893 CrossRefPubMedPubMedCentral

20.

Bragard I, Coucke PA (2013) Impact of the use of Luminette^® on well-being at work in a radiotherapy department. Cancer Radiother 17:731–735. https://doi.org/10.1016/j.canrad.2013.05.014 CrossRefPubMed

21.

Schmidt C, Xhrouet M, Hamacher M et al (2018) Light exposure via a head-mounted device suppresses melatonin and improves vigilant attention without affecting cortisol and comfort: head-mounted light, melatonin, vigilance, & comfort. PsyCh J 7:163–175. https://doi.org/10.1002/pchj.215 CrossRefPubMed

22.

Langevin RH, Laurent A, Sauvé Y (2014) Évaluation préliminaire de l’efficacité de la Luminette^® chez des adolescents atteints du syndrome de retard de phase du sommeil (SRPS): essai randomisé en simple insu et contrôlé par placebo. Médecine du Sommeil 11:91–97. https://doi.org/10.1016/j.msom.2014.03.003 CrossRef

23.

Paus S, Schmitz-Hübsch T, Wüllner U et al (2007) Bright light therapy in Parkinson’s disease: a pilot study. Mov Disord 22:1495–1498. https://doi.org/10.1002/mds.21542 CrossRefPubMed

24.

Willis GL, Moore C, Armstrong SM (2012) A historical justification for and retrospective analysis of the systematic application of light therapy in Parkinson’s disease. Rev Neurosci 23:199–226. https://doi.org/10.1515/revneuro-2011-0072 CrossRefPubMed

25.

Videnovic A, Klerman EB, Wang W et al (2017) Timed light therapy for sleep and daytime sleepiness associated with parkinson disease: a randomized clinical trial. JAMA Neurol 74:411–418. https://doi.org/10.1001/jamaneurol.2016.5192 CrossRefPubMedPubMedCentral

26.

Willis GL, Boda J, Freelance CB (2018) Polychromatic light exposure as a therapeutic in the treatment and management of Parkinson’s disease: a controlled exploratory trial. Front Neurol 9:741. https://doi.org/10.3389/fneur.2018.00741 CrossRefPubMedPubMedCentral

27.

Rutten S, Vriend C, Smit JH et al (2019) Bright light therapy for depression in Parkinson disease: a randomized controlled trial. Neurology 92:e1145–e1156. https://doi.org/10.1212/WNL.0000000000007090 CrossRefPubMed

28.

Research randomizer. https://www.randomizer.org/. Accessed 26 Apr 2019

29.

Zigmond AS, Snaith RP (1983) The hospital anxiety and depression scale. Acta Psychiatr Scand 67:361–370CrossRef

30.

Johns MW (1991) A new method for measuring daytime sleepiness: the Epworth sleepiness scale. Sleep 14:540–545CrossRef

31.

Fisk JD, Ritvo PG, Ross L et al (1994) Measuring the functional impact of fatigue: initial validation of the fatigue impact scale. Clin Infect Dis 18(Suppl 1):S79–S83CrossRef

32.

Johns M, Hocking B (1997) Daytime sleepiness and sleep habits of Australian workers. Sleep 20:844–849CrossRef

33.

Epworth Sleepiness Scale—The Official Website of the Epworth Sleepiness Scale (ESS & ESS-CHAD). http://epworthsleepinessscale.com/. Accessed 26 Apr 2019

34.

WMA—The World Medical Association-WMA declaration of Helsinki—ethical principles for medical research involving human subjects. https://www.wma.net/policies-post/wma-declaration-of-helsinki-ethical-principles-for-medical-research-involving-human-subjects/. Accessed 26 May 2019

Title: Bright light therapy with a head-mounted device for anxiety, depression, sleepiness and fatigue in patients with Parkinson’s disease
Authors: Jean-Marc Raymackers
Mariana Andrade
Eugenie Baey
Margaux Vanneste
Frédéric Evrard
Publication date: 01-12-2019
Publisher: Springer International Publishing
Keywords: Mood Disorders
Affective Disorder
Parkinson's Disease
Anxiety
Dopamine Agonist
Fatigue
Published in: Acta Neurologica Belgica / Issue 4/2019
Print ISSN: 0300-9009
Electronic ISSN: 2240-2993
DOI: https://doi.org/10.1007/s13760-019-01214-3

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Bright light therapy with a head-mounted device for anxiety, depression, sleepiness and fatigue in patients with Parkinson’s disease

Abstract

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 4/2019

Amyotrophic lateral sclerosis due to a SOD1 mutation and X-linked recessive bulbospinal neuronopathy in a single family

An adult case of metapneumovirus-induced acute encephalitis

Uncommon and/or bizarre features of dementia: part IV

Clinical approach to neurodegenerative disorders in childhood: an updated overview

A rare self-induced reflex epilepsy: sunflower syndrome

Clinical use of 99mTc-HMPAO-labeled platelets in cerebral sinus thrombosis imaging